Skip to main content
Log in

New UK regulatory measures for valproate use during pregnancy

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. including the risk of developmental disorders (up to 4 in every 10 babies exposed to valproate during pregnancy), and the risk of birth defects (approximately 1 in every 10 babies).

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

New UK regulatory measures for valproate use during pregnancy. Reactions Weekly 1701, 4 (2018). https://doi.org/10.1007/s40278-018-45836-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-45836-8

Navigation